Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox injection for painful symptomatic TMJ click
IRCT20130521013406N3Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of botulinum toxin type A in temporomandibular disorder (TMD) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Pain reduction and Joint sound reduction. Started Mar 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular disorder (TMD)
Beyond the preview
Go deeper on IRCT20130521013406N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130521013406N3.